Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2018-01-10 Capital/Financing Update
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Federal R&D Tax Credit Received 2 pages 80.8KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated January 11, 2018, stating that Phylogica Limited has received a cash refund under the Federal Government's R&D Tax Incentive Scheme for the 2017 financial year. It is a brief announcement about receiving a government tax credit refund related to R&D expenditure. There are no financial statements, detailed financial results, or management discussion. The document is short (1993 characters) and serves as an update on a financing-related event (receipt of government funds). This fits best under Capital/Financing Update (CAP) as it relates to a cash inflow impacting the company's capital resources. It is not an annual or interim report, earnings release, or regulatory filing. Therefore, the classification is CAP with high confidence.
2018-01-10 English
PYC Pivot to Platform - BioShowcase Presentation 21 pages 13.9MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation titled 'Phylogica: Pivot to Platform' dated January 2018, presented by the CSO Dr Robert Hayes. It contains slides with business updates, scientific data, market analysis, and strategic plans. The content is structured as a presentation aid with visuals and explanations, focusing on the company's platform technology, collaborations, and future goals. There is no indication that this is an official annual or quarterly report, audit report, or regulatory filing. It is not a transcript of a call, nor an announcement of voting results or dividends. The document fits the description of an Investor Presentation (IP), which is a detailed presentation for investors focusing on financials, strategy, and market position. The length (9873 characters) and content support this classification with high confidence.
2018-01-08 English
FPP Results Effective in Delivering Peptide Cancer Vaccine 4 pages 116.5KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Phylogica Limited dated January 8, 2018, describing preliminary results from animal model experiments demonstrating the efficacy of their Functional Penetrating Peptide (FPP) technology in delivering a peptide cancer vaccine. It also announces the filing of a new Australian provisional patent related to this technology. The content focuses on scientific results, patent filing, and future research plans. There are no financial statements, earnings data, management changes, or regulatory certifications. The document is a corporate announcement about research progress and patent activity rather than a financial report or regulatory filing. Therefore, it fits best under the category of a general regulatory announcement or compliance-related disclosure that does not fit other specific categories, which corresponds to Regulatory Filings (RNS). The document length (8389 characters) and detailed content confirm it is not a brief report publication announcement or a short notice.
2018-01-07 English
Appendix 3B and 3Y 15 pages 298.3KB
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement related to the issuance of new shares upon the exercise of options by Phylogica Limited. It includes an Appendix 3B, which is a standard form used in Australian Securities Exchange (ASX) filings for new issue announcements, and Appendix 3Y, which is a Change of Directors Interest Notice. The content focuses on the specifics of the share issuance, number of securities, terms, and related regulatory compliance information. There is no financial performance data, management discussion, or earnings information. The document is not a full annual or interim report, nor is it a call transcript or legal proceeding. It is a capital/financing update announcing new share issuance and related director interest changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2018-01-04 English
Appointment of Non-Executive Director and Appendix 3X 4 pages 472.3KB
Board/Management Information Classification · 100% confidence The document announces the appointment of a Non-Executive Director, Michael Williams, to the board of Phylogica Limited. It includes biographical details and statements from the CEO about the appointment. Additionally, it contains an Appendix 3X, which is an Initial Director's Interest Notice, reporting the director's relevant interests in securities as per regulatory requirements. There is no financial data, earnings information, or report content. The document is clearly an announcement related to changes in the company's board of directors. Therefore, it fits the category of Board/Management Information (MANG).
2018-01-02 English
Phylogica Strategic Update - Pivot to Platform 3 pages 128.9KB
Capital/Financing Update Classification · 90% confidence The document is an ASX announcement from Phylogica Limited providing a strategic update titled 'Pivot to Platform'. It discusses the company's shift in strategic priorities, focusing on commercializing its intracellular drug delivery platform technology and de-prioritizing internal product development programs. The document includes forward-looking statements about planned activities and milestones for 2018, but it does not contain any financial statements, detailed financial data, or regulatory filings. It is a corporate update aimed at informing investors and the market about strategic direction rather than a formal financial report or regulatory filing. Therefore, it fits best into the category of Capital/Financing Update (CAP), as it relates to strategic business direction and potential value creation for shareholders through focusing resources, which is typical for capital or strategic updates.
2017-12-03 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.